The primary aims of this study were to determine if inflammation-associated changes in upstream regulators of cortical NF-κB are different in people with schizophrenia than in non-schizophrenic controls, and to test the extent to which disease-associated changes in upstream regulators of cortical NF-κB would be consistent with those caused by a reduction in HIVEP2. Here, NFKB1 is linked to schizophrenia.